From 2017, François collaborates with Bio4Ward as a strategic and business development consultant, helping its pharmaceutical and biotech clients to devise and fund their growth strategies.

From 2012 to 2016, François was co-founder and CEO of Aquilon Pharmaceuticals (Liège - Belgium), a development-stage, spin-off company from University of Liège in the respiratory field.

From 2006 to 2012, he worked at GlaxoSmithKline Biologicals (Wavre – Belgium), in the Business Development and Strategic Alliances department, where he was responsible of completing the company’s vaccine adjuvant platform.

From 2004 to 2006, he worked at Innogenetics (Ghent – Belgium) in the Business Development department, where he was responsible of conducting negotiations for the company’s therapeutic assets (out-licensing of its late-stage portfolio in HCV therapeutic vaccine and in-licensing of its early-stage portfolio in HBV, HPV and HCV therapeutic vaccines).

After his studies, from 1997 to 2002, François worked at Puilaetco Investment Bank in the Corporate Finance department. After 2 years in the M&A division, he had a key role in setting-up the biotech franchise and led several private placements of pan-European biotech companies. François holds a master’s degree in Chemistry from University Libre de Bruxelles (1987 – 1991 - ULB – Belgium), a master of science in management from Solvay Business School (1991 – 1996) and an MBA from INSEAD (2002 – 2003).